SCHEMBL1500233

SCHEMBL1500233

O=c1[nH]c(=O)c2ccc(Br)cc2o1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
METAP2 P50579 1/20 0.43
PIM1 P11309 6/20 0.39
CHEK1 O14757 2/20 0.39
FLT3 P36888 2/20 0.39
AURKA O14965 1/20 0.39
DAPK3 O43293 1/20 0.39
JAK2 O60674 1/20 0.39
PRKD3 O94806 1/20 0.39
MAP4K4 O95819 1/20 0.39
PAK4 O96013 1/20 0.39
ABL1 P00519 1/20 0.39
NTRK1 P04629 1/20 0.39
CSF1R P07333 1/20 0.39
RET P07949 1/20 0.39
MET P08581 1/20 0.39
PDGFRB P09619 1/20 0.39
FGFR1 P11362 1/20 0.39
PDGFRA P16234 1/20 0.39
PRKACA P17612 1/20 0.39
FLT1 P17948 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1431071 0.85 PIM1 (0.50) PIM1CHEK1FLT3AURKADAPK3
SCHEMBL1071182 0.78 DAO (0.58) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL8777948 0.78 KDM4E (0.50) OGTNOS1NOS3NOS2LMNA
SCHEMBL2289312 0.78 NOS1 (0.62) PIM1CHEK1RPS6KA3NOS1NOS3
SCHEMBL6590835 0.78 MAOB (0.45) LMNACYP11B1CYP11B2
SCHEMBL25394296 0.78 KDM4E (0.55) KDRGSK3AGSK3BCDK5DYRK1A
SCHEMBL1762301 0.77 NOS1 (0.61) PIM1CHEK1FLT3AURKADAPK3
SCHEMBL17752292 0.74 CYP11B1 (0.54) METAP2PIM1TBK1CYP11B1CYP11B2
SCHEMBL30923496 0.74 CYP11B1 (0.54) METAP2PIM1TBK1CYP11B1CYP11B2
SCHEMBL2284104 0.74 KDM4E (0.57) LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110160208-A1 DIARYL-SUBSTITUTED FIVE-MEMBERED HETEROCYCLE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2011-06-30 US disclosed
US-7902369-B2 Diaryl-substituted five-membered heterocycle derivative BANYU PHARMACEUTICAL CO., LTD. (JP) 2011-03-08 US disclosed
US-20070173507-A1 Dairyl-substituted five-membered heterocycle derivative MSD K.K. (JP) 2007-07-26 US disclosed
EP-1726585-A1 DIARYL-SUBSTITUTED FIVE-MEMBERED HETEROCYCLE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2006-11-29 EP disclosed
US-4140532-A ORGANIC SILVER SALT, CATALYST, REDUCING AGENT, 2H-1,3-BENZOTHIAZIN-2,4(3H-)DIONE FUJI PHOTO FILM CO., LTD. (JP) 1979-02-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110160208-A1 DIARYL-SUBSTITUTED FIVE-MEMBERED HETEROCYCLE DERIVATIVE OPRK1, GRM1, GRIK1 METAP2 4027/4885PIM1 3102/4885CHEK1 3956/4885
US-20070173507-A1 Dairyl-substituted five-membered heterocycle derivative OPRK1, OPRL1, GRM1 METAP2 3567/4885PIM1 2634/4885CHEK1 3873/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.